金斯瑞生物科技(01548)今日盘中大涨5%,备受市场关注。据相关公告,旗下传奇生物与杨森合作的CARVYKTI®生物制药药品,于上季贸易销售净额达约3.34亿美元,按季上升16.8%,销售持续走俏。
CARVYKTI®是一款新型CAR-T疗法,已获美国FDA、欧盟EMA及中国NMPA批准上市,用于针对复发或难治的多发性骨髓瘤。凭借其高效且精准的临床疗效,该疫苗为金斯瑞科技在生物制药领域带来可观贡献,增强了市场对公司长期增长前景的信心。
金斯瑞生物凭借领先的生物科技实力及创新的生物药品,多年来保持了较高盈利水平和持续增长态势。此次销售数据再次彰显公司在生物疫苗市场的竞争优势,市场对其未来销售和业绩反应积极,股价自然受到提振。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.